Bernhard D.
- Country
- Austria
- Department
- Department of Internal Medicine I; Division of Medical Oncology and Haematology
Research Overview
- Phase 2/3 Randomized Study of Telisotuzumab Adizutecan Combined with FOLFOX versus Standard of Care in First‑Line Metastatic Pancreatic Ductal Adenocarcinoma
- Evaluation of BI 907828 Monotherapy in Patients with MDM2-Amplified, TP53 Wild-Type Biliary Tract, Pancreatic, Lung, and Urothelial Bladder Cancers
- Phase III Randomized Controlled Trial Evaluating Tinengotinib Versus Physician's Choice in FGFR-Altered, Chemotherapy- and FGFR Inhibitor-Refractory Cholangiocarcinoma
Data & Insights
Has run more than one trial at 76 of 191 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating biliary tract cancers, with particular focus on cholangiocarcinoma and gallbladder cancer. Their research extends to innovative treatments for pancreatic ductal adenocarcinoma, demonstrating expertise in complex gastrointestinal malignancies.
- Biliary Tract Adenocarcinoma
- Cholangiocarcinoma Management
- Pancreatic Cancer Treatment
Targeted Therapies
The investigator focuses on developing treatments targeting Fibroblast Growth Factor Receptor (FGFR) alterations in cancer. Their work includes evaluating novel therapeutic approaches for patients who have developed resistance to conventional treatments.
- FGFR Inhibitor Development
- Drug Resistance Mechanisms
- Molecular Targeted Therapies
Additional Oncology Focus
The investigator's expertise extends to treating lung adenocarcinoma and urothelial bladder cancer, showcasing comprehensive knowledge in multiple cancer types and their treatment modalities.
- Lung Cancer Treatment
- Bladder Cancer Management
- Multi-cancer Treatment Approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.